A Life sciences venture capital firm come to Halloran looking for help prioritizing potential indications for their lead oncology compound.
- Halloran drew from experience, guidelines, and precedence to determine the optimal development strategy and clinical and regulatory considerations, including ballpark costs and timeframes, for 8 potential indications.
- Halloran outlined risks and potential roadblocks for each of the selected indications, ranked by severity
- Halloran provided a clear-cut and effective methodology for scoring the potential 8 indications
The client was able to confidently prioritize development of indication and progress swiftly to go/no-go indication decisions. Halloran’s expertise was able to guide leadership to the most efficient pathway to market.